LTR PharmaASX:LTP -4.27%15 PB Ratio is 3.78 as of Jun. 27, 2026, which is 38% above its 10-year median of 2.73. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, LTR Pharma ranks worse than 63.64% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), LTR Pharma's share price is A$0.56. LTR Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.15. Hence, LTR Pharma's PB Ratio of today is 3.78.
Warning Sign:
LTR Pharma Ltd stock PB Ratio (=3.99) is close to 1-year high of 4.22.
The historical rank and industry rank for LTR Pharma's PB Ratio or its related term are showing as below:
ASX:LTP'
s PB Ratio Range Over the Past 10 Years
Min: 1.64 Med: 2.73 Max: 4.22
Current: 3.79
During the past 5 years, LTR Pharma's highest PB Ratio was 4.22. The lowest was 1.64. And the median was 2.73.
ASX:LTP's PB Ratio is ranked worse than 63.64% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ASX:LTP: 3.79
During the past 12 months, LTR Pharma's average Book Value Per Share Growth Rate was -22.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 137.40% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of LTR Pharma was 137.40% per year. The lowest was 137.40% per year. And the median was 137.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
LTR Pharma PB Ratio Related Terms
LTR Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for LTR Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LTR Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where LTR Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
LTR Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
LTR Pharma (ASX:LTP) has a PB Ratio of 3.78 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on LTR Pharma and its competitors. This is 38% above median its historical median of 2.73. Over the past decade, LTR Pharma's PB Ratio has ranged from 1.64 to 4.22. According to the industry distribution chart, LTR Pharma ranks #784 out of 1232 companies in the Biotechnology industry, placing it in the top 63.6%.
Is LTR Pharma's PB Ratio too high?
LTR Pharma's current PB Ratio of 3.78 is 38% above median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 4.22. The Biotechnology industry median PB Ratio is 2.80. LTR Pharma's value of 3.78 is 35% above this industry median. Based on the distribution chart, LTR Pharma ranks #784 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #784 out of 1232 companies for PB Ratio. This places LTR Pharma in the lower half of its industry. The industry median PB Ratio is 2.80. LTR Pharma's value of 3.78 is 35% above this benchmark. Historically, LTR Pharma's own PB Ratio has ranged from 1.64 to 4.22 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 2.80, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current PB Ratio of 3.78 is 35% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current PB Ratio is 3.78, which is 38% above median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current PB Ratio of 3.78. The current PB Ratio is 3.78, which is 38% above median its 10-year median of 2.73 and 35% above the Biotechnology industry median of 2.80. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current PB Ratio is 3.78 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 